Morgan Koontz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Morgan Koontz has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Rafi Aibani
Hematology/Oncology Department, Charleston Area Medical Center, Charleston, WV
2 shared publications - Amir Kamran
CAMC, Department of Hematology and Medical Oncology, Charleston, USA
1 shared publication - Carol Faris
Department of Internal Medicine, Bayonne Medical Center, Bayonne, NJ 07002, USA
1 shared publication - Ebubekir Daglilar
Charleston Area Medical Center, Charleston, WV 25304, USA
1 shared publication - Harleen Kaur Chela
Division of Gastroenterology and Hepatology, Charleston Area Medical Center, West Virginia University, Charleston, WV 25302, USA
1 shared publication - James Stephen Harman
Neurosurgery West Virginia University, Charleston Area Medical Center, Charleston, WV, USA
1 shared publication
Latest Publications
- Open Access
- 5 May 2025
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 15 (3) , 68-72
Reversible Cerebral Vasoconstriction Syndrome Induced by Sumatriptan: A Case Report and Review of Literature.
Background Reversible Cerebral Vasoconstriction Syndrome (RCVS) is characterized by multiple transient cerebral vasoconstrictions that typically resolve within three months, often presenting with sudden thunderclap headaches. Although the cause can be identified in 25% to 60% of cases, RCVS can also occur spontaneously. Common triggers include vasoactive substances and postpartum states, with the latter accounting for 50% to 60% of cases. This report discusses a case of RCVS following sumatriptan use. Case Report. A 58-year-old woman with controlled hypertension and obstructive sleep apnea presented with recurrent unilateral pulsating headaches, nausea, and photophobia. Initially diagnosed as migraine, she later developed right homonymous hemianopia. Imaging revealed bilateral occipital and parietal strokes with intracranial vasoconstriction. Cerebral angiography confirmed vasospasm, responsive to intra-arterial milrinone. Diagnosed with reversible cerebral vasoconstriction syndrome, she was treated with nimodipine, resulting in complete symptom resolution. Conclusion RCVS is a rare syndrome with varied triggers and clinical features, requiring careful evaluation and management. Early diagnosis and vasospasm-targeted therapies, such as nimodipine, are essential for preventing complications. This case underscores the importance of considering RCVS in patients with sudden severe headaches and neurological deficits, particularly those using serotonergic medications
- 5 May 2025
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 15 (3) , 68-72
Open AccessReversible Cerebral Vasoconstriction Syndrome Induced by Sumatriptan: A Case Report and Review of Literature.
Background Reversible Cerebral Vasoconstriction Syndrome (RCVS) is characterized by multiple transient cerebral vasoconstrictions that typically resolve within three months, often presenting with sudden thunderclap headaches. Although the cause can be identified in 25% to 60% of cases, RCVS can also occur spontaneously. Common triggers include vasoactive substances and postpartum states, with the latter accounting for 50% to 60% of cases. This report discusses a case of RCVS following sumatriptan use. Case Report. A 58-year-old woman with controlled hypertension and obstructive sleep apnea presented with recurrent unilateral pulsating headaches, nausea, and photophobia. Initially diagnosed as migraine, she later developed right homonymous hemianopia. Imaging revealed bilateral occipital and parietal strokes with intracranial vasoconstriction. Cerebral angiography confirmed vasospasm, responsive to intra-arterial milrinone. Diagnosed with reversible cerebral vasoconstriction syndrome, she was treated with nimodipine, resulting in complete symptom resolution. Conclusion RCVS is a rare syndrome with varied triggers and clinical features, requiring careful evaluation and management. Early diagnosis and vasospasm-targeted therapies, such as nimodipine, are essential for preventing complications. This case underscores the importance of considering RCVS in patients with sudden severe headaches and neurological deficits, particularly those using serotonergic medications
- Open Access
Thrombotic Long-Term Consequences of SARS-CoV-2 Infection in Patients with Compensated Cirrhosis: A Propensity Score-Matched Analysis of a U.S. Database
Background: Cirrhosis causes an imbalance in the coagulation pathway and leads to a tendency for both bleeding and clotting. SARS-CoV-2 has been reported to be associated with a hypercoagulable state. This study examines SARS-CoV-2’s impact on hemostasis in compensated patients with cirrhosis. Methods: We analyzed the US Collaborative Network, which comprises 63 HCOs in the U.S.A. Compensated cirrhosis patients were split into two groups: SARS-CoV-2-positive and -negative. Patients’ baseline characteristics were used in a 1:1 propensity score-matched module to create comparable cohorts. We compared the risk of portal vein thrombosis (PVT), deep venous thrombosis (DVT), and pulmonary embolism (PE) at 6 months, and 1 and 3 years. Results: Of 330,521 patients, 27% tested positive and 73% remained negative. After PSM, both cohorts included 74,738 patients. Patients with SARS-CoV-2 had a higher rate of PVT compared to those without at 6 months (0.63% vs 0.5%, p < 0.05), 1 year (0.8% vs 0.6%, p < 0.05), and 3 years (1% vs. 0.7%, p < 0.05), a higher rate of DVT at 6 months (0.8% vs. 0.4%, p < 0.05), 1 year (1% vs. 0.5%, p < 0.05), and 3 years (1.4% vs. 0.8%, p < 0.05), and a higher rate of PE at 6 months (0.6% vs. 0.3%, p < 0.05), 1 year (0.7% vs. 0.4%, p < 0.05), and 3 years (1% vs. 0.6%, p < 0.05). Conclusions: The presence of SARS-CoV-2 infection in patients with compensated cirrhosis was associated with a higher rate of PVT, DVT, and PE at 6 months, and 1 and 3 years.
Open AccessThrombotic Long-Term Consequences of SARS-CoV-2 Infection in Patients with Compensated Cirrhosis: A Propensity Score-Matched Analysis of a U.S. Database
Background: Cirrhosis causes an imbalance in the coagulation pathway and leads to a tendency for both bleeding and clotting. SARS-CoV-2 has been reported to be associated with a hypercoagulable state. This study examines SARS-CoV-2’s impact on hemostasis in compensated patients with cirrhosis. Methods: We analyzed the US Collaborative Network, which comprises 63 HCOs in the U.S.A. Compensated cirrhosis patients were split into two groups: SARS-CoV-2-positive and -negative. Patients’ baseline characteristics were used in a 1:1 propensity score-matched module to create comparable cohorts. We compared the risk of portal vein thrombosis (PVT), deep venous thrombosis (DVT), and pulmonary embolism (PE) at 6 months, and 1 and 3 years. Results: Of 330,521 patients, 27% tested positive and 73% remained negative. After PSM, both cohorts included 74,738 patients. Patients with SARS-CoV-2 had a higher rate of PVT compared to those without at 6 months (0.63% vs 0.5%, p < 0.05), 1 year (0.8% vs 0.6%, p < 0.05), and 3 years (1% vs. 0.7%, p < 0.05), a higher rate of DVT at 6 months (0.8% vs. 0.4%, p < 0.05), 1 year (1% vs. 0.5%, p < 0.05), and 3 years (1.4% vs. 0.8%, p < 0.05), and a higher rate of PE at 6 months (0.6% vs. 0.3%, p < 0.05), 1 year (0.7% vs. 0.4%, p < 0.05), and 3 years (1% vs. 0.6%, p < 0.05). Conclusions: The presence of SARS-CoV-2 infection in patients with compensated cirrhosis was associated with a higher rate of PVT, DVT, and PE at 6 months, and 1 and 3 years.